Compare · ECOR vs LIVN
ECOR vs LIVN
Side-by-side comparison of electroCore Inc. (ECOR) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ECOR and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.19B, about 56.7x ECOR ($73.9M).
- Over the past year, ECOR is up 64.9% and LIVN is up 45.7% - ECOR leads by 19.2 points.
- LIVN has been more active in the news (2 items in the past 4 weeks vs 1 for ECOR).
- LIVN has more recent analyst coverage (21 ratings vs 2 for ECOR).
- Company
- electroCore Inc.
- LivaNova PLC
- Price
- $8.41+3.32%
- $78.52+3.25%
- Market cap
- $73.9M
- $4.19B
- 1M return
- -18.31%
- -0.03%
- 1Y return
- +64.90%
- +45.69%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 1
- 2
- Recent ratings
- 2
- 21
electroCore Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest ECOR
- Director Errico Thomas J. bought $49,082 worth of shares (5,000 units at $9.82), increasing direct ownership by 1% to 363,904 units (SEC Form 4)
- Amendment: Officer Fox Michael bought $49,004 worth of shares (5,000 units at $9.80), increasing direct ownership by 4% to 130,000 units (SEC Form 4)
- Officer Fox Michael was granted 5,000 shares, increasing direct ownership by 4% to 130,000 units (SEC Form 4)
- Director Theofilos James Charles was granted 11,123 shares, increasing direct ownership by 47% to 34,670 units (SEC Form 4)
- Director Goldstein Julie Ann was granted 11,123 shares, increasing direct ownership by 11% to 112,510 units (SEC Form 4)
- Director Wilber Patricia was granted 11,123 shares, increasing direct ownership by 15% to 83,448 units (SEC Form 4)
- Director Errico Thomas J. was granted 15,572 shares, increasing direct ownership by 5% to 358,904 units (SEC Form 4)
- Director Bonfiglioli Elena was granted 11,123 shares, increasing direct ownership by 36% to 41,672 units (SEC Form 4)
- Officer Fox Michael was granted 55,000 shares, increasing direct ownership by 79% to 125,000 units (SEC Form 4)
- Officer Lev Joshua S. was granted 55,000 shares, increasing direct ownership by 65% to 139,889 units (SEC Form 4)
Latest LIVN
- Barclays initiated coverage on LivaNova with a new price target
- LivaNova to Announce Third-Quarter 2026 Results
- SEC Form 4 filed by Chief Legal Officer Liddy Anne M.
- Director Bianchi Francesco sold $273,032 worth of Ordinary Shares (3,500 units at $78.01), decreasing direct ownership by 44% to 4,434 units (SEC Form 4)
- Director Story Brooke sold $187,270 worth of Ordinary Shares (2,300 units at $81.42), decreasing direct ownership by 23% to 7,488 units (SEC Form 4)
- LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
- Director Bianchi Francesco sold $131,538 worth of Ordinary Shares (1,650 units at $79.72), decreasing direct ownership by 17% to 7,934 units (SEC Form 4)
- SEC Form 3 filed by new insider Liddy Anne M.
- Chief Innovation Officer Tezel Ahmet exercised 12,692 units of Ordinary Shares at a strike of $52.68, returned $668,740 worth of Ordinary Shares to the company (8,589 units at $77.86), covered exercise/tax liability with 1,428 units of Ordinary Shares and sold $207,942 worth of Ordinary Shares (2,675 units at $77.74) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by LivaNova PLC